Cell interventions and longevity: define a clinical question instead of promising anti-ageing
Ageing is not one treatable indication, and a change in a biomarker does not prove longer life, broader healthspan or reversal of ageing.
Replace the broad anti-ageing claim with a defined population and clinical problem, such as a recognised frailty syndrome, impaired mobility or another diagnosed condition. Specify baseline risk, established care and a clinically meaningful goal. Marketing to healthy people requires a different benefit-risk justification from treating disease.
Define the exact product and mechanism as a hypothesis: source, donor relationship, manipulation, dose, route, schedule, manufacturer and release tests. MSCs from different tissues and processes, immune-cell products, plasma-derived interventions and exosomes cannot be grouped as one longevity treatment.
Separate outcome levels. Walking performance, strength, daily function, hospitalisation, quality of life, adverse events, inflammatory markers and epigenetic clocks answer different questions. A biomarker movement is not evidence of rejuvenation unless it is validated as a surrogate for the claimed patient benefit.
Use controlled, prospectively registered studies with adequate follow-up and transparent missing data. Report absolute effects, uncertainty, serious adverse events and durability. Do not infer lifespan extension from a short study, a subgroup, animal work or a shift between frailty categories without the prespecified analysis.
Verify whether the product is authorised for the exact indication or used in an authorised trial. The EMA/HMA warning applies to unregulated ATMPs marketed online, while the ISSCR patient guide distinguishes research from unproven treatment. Longevity branding does not lower the evidence or consent standard.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.